Long-term treatment risks in multiple sclerosis: Risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients

Multiple Sclerosis Journal

Volumn 19, Issue 7, 2013, Pages 920-925

  Hofmann, A ^a   Stellmann, J P ^a   Kasper, J ^a,b   Ufer, F ^a   Elias, W G ^c   Pauly, I ^d   Repenthin, J ^e   Rosenkranz, T ^f   Weber, T ^c   Kopke S ^a,g   Heesen, C ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c Unit of Health Science and Education University of Hamburg ^*  (Germany)

^d Asklepios Klinik Nord Heidberg   (Germany)

^e ASKLEPIOS HOSPITAL BARMBEK   (Germany)

^f DEPARTMENT OF CARDIOLOGY   (Germany)

^g UNIVERSITY OF LÜBECK   (Germany)

Author keywords

cardiotoxicity; leukaemia; mitoxantrone; Multiple sclerosis; patient information; progressive

Indexed keywords

MITOXANTRONE;

ADULT; ARTICLE; CARDIOTOXICITY; COHORT ANALYSIS; DISEASE DURATION; FEMALE; GERMANY; HUMAN; LEUKEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT DURATION;

EID: 84878366822     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512461967     Document Type: Article

References (30)

1. Moulton B, King JS. Aligning ethics with medical decision-making: The quest for informed patient choice. J Law Med Ethics. 2010 ;: 85-97
2. Gigerenzer G, Gaissmaier W, Kurz-Milcke E, et al. Helping doctors and patients make sense of health statistics. Psychol Sci. 2008 ; 8: 53-96
3. Schwartz LM, Woloshin S, Welch HG. Can patients interpret health information? An assessment of the medical data interpretation test. Med Decis Making. 2005 ; 25: 290-300
4. Bunge M, Mühlhauser I, Steckelberg A. What constitutes evidence-based patient information? Overview of discussed criteria. Patient Educ Couns. 2010 ; 78: 316-328
5. Heesen C, Segal J, Reich C, et al. Patient information on cognitive symptoms in multiple sclerosis - acceptability in relation to disease duration. Acta Neurol Scand. 2006 ; 114: 268-272
6. Kasper J, Köpke S, Mühlhauser I, et al. Evidence-based patient information about treatment of multiple sclerosis - a phase one study on comprehension and emotional responses. Patient Educ Couns. 2006 ; 62: 56-63
7. Heesen C, Schäffler N, Kasper J, et al. Suspected multiple sclerosis - what to do? Evaluation of a patient information leaflet. Mult Scler. 2009 ; 15: 1103-1112
8. Luce MF. Decision making as coping. Health Psychol. 2005 ; 24: S23 - S28
9. Mohr DC, Pelletier D. A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis. Brain Behav Immun. 2006 ; 20: 27-36
10. Heesen C, Kleiter I, Nguyen F, et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult Scler. 2010 ; 16: 1507-1512
11. Hartung H-P, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002 ; 360: 2018-2025
12. Ghalie R, Mauch E, Edan G, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler. 2002 ; 8: 441-445
13. Martinelli V, Cocco E, Capra R, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology. 2011 ; 77: 1887-1895
14. Le Page E, Leray E, Edan G. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: A 5-year prospective study. Mult Scler. 2011 ; 17: 867-875
15. Pascual AM, Téllez N, Boscá I, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler. 2009 ; 15: 1303-1310
16. Stroet A, Hemmelmann C, Starck M, et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord. 2012 ; 5: 75-79
17. Martinelli V, Radaelli M, Straffi L, et al. Mitoxantrone: Benefits and risks in multiple sclerosis patients. Neurol Sci. 2009 ; 30: S167 - S170
18. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology. 2002 ; 59: 909-913
19. Martinelli Boneschi F, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2005 ;:
20. Dangond F, Dawson D, Beagan J, et al. Cardiovascular adverse events with mitoxantrone: Results from the registry to evaluate Novantrone effects in worsening multiple sclerosis (RENEW) study. Programs and abstracts of the 62nd American Academy of Neurology Annual Meeting ; Toronto, Canada ;. 10.
21. Marriott JJ, Miyasaki JM, Gronseth G, et al. Evidence report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010 ; 74: 1463-1470
22. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012 ; 366: 339-347
23. Hein T, Hopfenmüller W. Hochrechnung der Zahl an Multiple Sklerose erkrankten Patienten in Deutschland. Der Nervenarzt. 2000 ; 71: 288-294
24. Heesen C, Solari A, Giordano A, et al. Decisions on multiple sclerosis immunotherapy: New treatment complexities urge patient engagement. J Neurol Sci. 2011 ; 306: 192-197
25. Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology. 2012 ; 78: 436-437
26. Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol. 2009 ; 22: 295-302
27. Heshka JT, Palleschi C, Howley H, et al. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med. 10: 19-32
28. Clarke VA, Lovegrove H, Williams A, et al. Unrealistic optimism and the health belief model. J Behav Med. 2000 ; 23: 367-376
29. Butow PN, Lobb EA, Meiser B, et al. Psychological outcomes and risk perception after genetic testing and counselling in breast cancer: A systematic review. Med J Aust. 2003 ; 178: 77-81
30. Liu Y, Pérez M, Schootman M, et al. A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer. Breast Cancer Res Treat. 2010 ; 124: 835-844